{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:45:34Z","timestamp":1791873934351,"version":"4.3.4"},"reference-count":184,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Secukinumab is an anti-interleukin (IL)-17A IgG1-\u03ba monoclonal antibody approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Its efficacy is well documented, but the complete safety profile of secukinumab, especially on long-term use, needs to be studied. IL-17 inhibitors increase the risk of infections, especially respiratory tract infections and candidiasis, and inflammatory bowel disease; the causal relationships are well described. However, evidence regarding the other adverse events is scarce, and causal associations between the adverse events and the biologic remain unresolved. This review aims to present a narrative perspective on the safety of secukinumab and identify some key areas where the safety of secukinumab may potentially be useful in understanding the scope of secukinumab therapy and making informed clinical decisions.<\/jats:p>","DOI":"10.3390\/ph15111365","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T10:49:51Z","timestamp":1667904591000},"page":"1365","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["A Review of the Safety of Interleukin-17A Inhibitor Secukinumab"],"prefix":"10.3390","volume":"15","author":[{"given":"Vishnu","family":"Eshwar","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9609-0199","authenticated-orcid":false,"given":"Ashwin","family":"Kamath","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeshwari","family":"Shastry","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-7582","authenticated-orcid":false,"given":"Ashok K.","family":"Shenoy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Kamath","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A Distinct Lineage of CD4 T Cells Regulates Tissue Inflammation by Producing Interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and Type 17 Helper T Cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"741","DOI":"10.12688\/f1000research.10862.1","article-title":"Yin and Yang of Interleukin-17 in Host Immunity to Infection","volume":"6","author":"Khader","year":"2017","journal-title":"F1000Research"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0001-7310(14)70017-1","article-title":"Role of IL-17 and IL-22 in Autoimmunity and Cancer","volume":"105","author":"Blake","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 Family of Cytokines in Health and Disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e20190297","DOI":"10.1084\/jem.20190297","article-title":"The Role of Interleukin-17 in Tumor Development and Progression","volume":"217","author":"Zhao","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_8","unstructured":"(2022, April 06). Targeting IL-17 in Inflammatory Disease. Available online: https:\/\/www.nature.com\/collections\/vzdlng."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis with Biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/09546634.2020.1737638","article-title":"Off-Label Dermatologic Uses of IL-17 Inhibitors","volume":"33","author":"Wu","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/cea.13616","article-title":"Interleukin-17 Is a Potential Player and Treatment Target in Severe Chronic Spontaneous Urticaria","volume":"50","author":"Sabag","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"AB88","DOI":"10.1016\/j.jaad.2020.06.441","article-title":"17965 An Exploratory, Open-Label Study of Secukinumab in Patients with Moderate to Severe Papulopustular Rosacea","volume":"83","author":"Kumar","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1002\/ski2.25","article-title":"Efficacy and Safety of Secukinumab for the Treatment of Severe ABCA12 Deficiency-Related Ichthyosis in a Child","volume":"1","author":"Yogarajah","year":"2021","journal-title":"Skin Health Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2040622317738910","article-title":"Secukinumab: A Review of the Anti-IL-17A Biologic for the Treatment of Psoriasis","volume":"9","author":"Frieder","year":"2018","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab Long-Term Safety Experience: A Pooled Analysis of 10 Phase II and III Clinical Studies in Patients with Moderate to Severe Plaque Psoriasis","volume":"75","author":"Kerkhof","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-Reporting of Adverse Drug Reactions: A Systematic Review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"adv00698","DOI":"10.2340\/actadv.v102.563","article-title":"Long-Term Safety of Secukinumab Over Five Years in Patients with Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-Marketing Surveillance Data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm. Venereol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet Lond. Engl."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of Psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03240.x","article-title":"Interleukin-17 and Its Target Genes: Mechanisms of Interleukin-17 Function in Disease","volume":"129","author":"Onishi","year":"2010","journal-title":"Immunology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2147\/ITT.S240891","article-title":"The Role of IL-17 Cytokines in Psoriasis","volume":"10","author":"Mosca","year":"2021","journal-title":"ImmunoTargets Ther."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Furue, M., Furue, K., Tsuji, G., and Nakahara, T. (2020). Interleukin-17A and Keratinocytes in Psoriasis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041275"},{"key":"ref_26","first-page":"ii14","article-title":"Psoriatic Arthritis: Epidemiology, Clinical Features, Course, and Outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3389\/fmed.2018.00364","article-title":"IL-17 in Rheumatoid Arthritis and Precision Medicine: From Synovitis Expression to Circulating Bioactive Levels","volume":"5","author":"Robert","year":"2019","journal-title":"Front. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41413-019-0057-8","article-title":"Ankylosing Spondylitis: Etiology, Pathogenesis, and Treatments","volume":"7","author":"Zhu","year":"2019","journal-title":"Bone Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial Spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet Lond. Engl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10928","DOI":"10.1038\/ncomms10928","article-title":"IL-17-Producing \u0393\u03b4 T Cells Enhance Bone Regeneration","volume":"7","author":"Ono","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2147\/TCRM.S100091","article-title":"Secukinumab for Ankylosing Spondylitis and Psoriatic Arthritis","volume":"12","author":"Lubrano","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/09546634.2015.1054782","article-title":"Biologics and Biosimilars","volume":"26","author":"Patel","year":"2015","journal-title":"J. Dermatol. Treat."},{"key":"ref_33","unstructured":"Center for Biologics Evaluation and Research (2019). What Are \u201cBiologics\u201d Questions and Answers, FDA."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nrrheum.2014.123","article-title":"Adverse Reactions to Biologic Agents and Their Medical Management","volume":"10","author":"Boyman","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.crohns.2012.06.024","article-title":"The Complexity of Adverse Side-Effects to Biological Agents","volume":"7","author":"Aubin","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/art.27334","article-title":"LY2439821, a Humanized Anti-Interleukin-17 Monoclonal Antibody, in the Treatment of Patients with Rheumatoid Arthritis: A Phase I Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study","volume":"62","author":"Genovese","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/bcp.13185","article-title":"First-in-Human Randomized Study of Bimekizumab, a Humanized Monoclonal Antibody and Selective Dual Inhibitor of IL-17A and IL-17F, in Mild Psoriasis","volume":"83","author":"Glatt","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an Anti\u2013Interleukin-17\u2013Receptor Antibody for Psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_41","unstructured":"(2017). SILIQTM [Package Insert], Valeant Pharmaceuticals."},{"key":"ref_42","unstructured":"(2016). TALTZTM [Package Insert], Eli Lily and Company."},{"key":"ref_43","unstructured":"(2015). COSENTYXTM [Package Insert], Novartis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1398-9995.2006.01058.x","article-title":"Adverse Side-Effects to Biological Agents","volume":"61","author":"Pichler","year":"2006","journal-title":"Allergy"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2546161","DOI":"10.1155\/2019\/2546161","article-title":"Short-Term Efficacy and Safety of IL-17, IL-12\/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials","volume":"2019","author":"Bai","year":"2019","journal-title":"J. Immunol. Res."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Barbieri, M.A., Cicala, G., Cutroneo, P.M., Gerratana, E., Palleria, C., Sarro, C.D., Vero, A., Iannone, L., Manti, A., and Russo, E. (2020). Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study. J. Clin. Med., 9.","DOI":"10.3390\/jcm9041227"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Iannone, L.F., Bennardo, L., Palleria, C., Roberti, R., de Sarro, C., Naturale, M.D., Dastoli, S., Donato, L., Manti, A., and Valenti, G. (2020). Safety Profile of Biologic Drugs for Psoriasis in Clinical Practice: An Italian Prospective Pharmacovigilance Study. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0241575"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s13555-021-00675-w","article-title":"Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study","volume":"12","author":"Foley","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/1346-8138.15655","article-title":"Safety and Effectiveness of Secukinumab in Psoriasis Vulgaris and Psoriatic Arthritis: Real-world Evidence in Japan","volume":"48","author":"Fujita","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-020-02208-w","article-title":"Efficacy and Safety of IL-17 Inhibitors for the Treatment of Ankylosing Spondylitis: A Systematic Review and Meta-Analysis","volume":"22","author":"Yin","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Maddur, M.S., Vani, J., Lacroix-Desmazes, S., Kaveri, S., and Bayry, J. (2010). Autoimmunity as a Predisposition for Infectious Diseases. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001077"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/pds.5132","article-title":"Risk of Common Infections among Individuals with Psoriasis in Sweden: A Nationwide Cohort Study Comparing Secukinumab to Ustekinumab","volume":"29","author":"Srinivas","year":"2020","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10787-022-00933-z","article-title":"Immune-Related Adverse Events (IrAEs) in Ankylosing Spondylitis (AS) Patients Treated with Interleukin (IL)-17 Inhibitors: A Systematic Review and Meta-Analysis","volume":"30","author":"Azadeh","year":"2022","journal-title":"Inflammopharmacology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.rdc.2016.09.005","article-title":"Opportunistic Infections in Biological Therapy, Risk and Prevention","volume":"43","author":"Bryant","year":"2017","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European Evidence-Based Consensus on the Prevention, Diagnosis and Management of Opportunistic Infections in Inflammatory Bowel Disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J. Crohns Colitis"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2020.3257","article-title":"Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis","volume":"157","author":"Elewski","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/09546634.2019.1597246","article-title":"Risk of Herpes Zoster with IL-17 Inhibitor Therapy for Psoriasis and Other Inflammatory Conditions","volume":"31","author":"Wu","year":"2019","journal-title":"J. Dermatol. Treat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/14712598.2022.2029841","article-title":"Secukinumab for the Treatment of Palmoplantar Psoriasis: A 2-Year, Multicenter, Real-Life Observational Study","volume":"22","author":"Galluzzo","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1111\/ajd.13588","article-title":"Secukinumab and Infectious Adverse Effects: A Real-Life Experience of 63 Psoriasis Patients","volume":"62","author":"Ergun","year":"2021","journal-title":"Australas. J. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"225","DOI":"10.25259\/IJDVL_496_2021","article-title":"Epithelial Herpes Simplex Keratitis in a Patient on Treatment with Secukinumab for Psoriasis: An Effect of Interleukin-17 Blockade?","volume":"88","author":"Sinha","year":"2022","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_61","first-page":"477","article-title":"Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated with Biologics: A Retrospective Analysis of 20 Cases from the BIOBADADERM Database","volume":"106","author":"Vanaclocha","year":"2015","journal-title":"Actas Dermosifiliogr."},{"key":"ref_62","first-page":"613","article-title":"Risk of Hepatitis B Virus Reactivation in Patients on Secukinumab for Psoriasis: A Series of 4 Cases","volume":"111","year":"2020","journal-title":"Actas Dermo-Sifiliogr. Engl. Ed."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"101156","DOI":"10.1016\/j.ajoc.2021.101156","article-title":"Bilateral Infectious Scleritis from Histoplasma Capsulatum in an Immunosuppressed Uveitis Patient","volume":"23","author":"Wang","year":"2021","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/pde.14228","article-title":"Staphylococcal Toxic Shock Syndrome in a Child with Interleukin-17 Inhibitor Treatment for Psoriasis","volume":"37","year":"2020","journal-title":"Pediatr. Dermatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/ced.14844","article-title":"Infective Dermatitis after Treatment with Secukinumab","volume":"47","author":"Utiyama","year":"2022","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/ijd.15679","article-title":"Skin and Soft Tissue Infections in Biological Therapy for Psoriasis\u2014A Case Report and Systematic Review of the Literature","volume":"60","author":"Fisher","year":"2021","journal-title":"Int. J. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"ofy146","DOI":"10.1093\/ofid\/ofy146","article-title":"Breech at the Border: An Atypical Case of Invasive Haemophilus Influenzae in a Patient on a Novel Immunotherapeutic","volume":"5","author":"Satola","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.clindermatol.2007.08.015","article-title":"Triggering Psoriasis: The Role of Infections and Medications","volume":"25","author":"Fry","year":"2007","journal-title":"Clin. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Mengesha, B.G., and Conti, H.R. (2017). The Role of IL-17 in Protection against Mucosal Candida Infections. J. Fungi, 3.","DOI":"10.3390\/jof3040052"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","article-title":"Long-Term Safety of Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Integrated Pooled Clinical Trial and Post-Marketing Surveillance Data","volume":"21","author":"Deodhar","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_71","first-page":"100266","article-title":"Risk of Candidiasis Associated with Interleukin-17 Inhibitors: A Real-World Observational Study of Multiple Independent Sources","volume":"13","author":"Davidson","year":"2022","journal-title":"Lancet Reg. Health-Eur."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Picciani, B.L.S., Dziedzic, A., Werneck, J.T., Marinho, M.A., Dick, T.N.A., Quintanilha, N.R., and Dias, E.P. (2021). Atypical Oral Candidiasis in a Psoriatic Patient during Targeted Immunotherapy with an Interleukin 17 Inhibitor (Secukinumab). BMC Oral. Health, 21.","DOI":"10.1186\/s12903-021-01653-6"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"584","DOI":"10.5021\/ad.2021.33.6.584","article-title":"Abrupt Development of Esophageal Candidiasis after Secukinumab Treatment in a Psoriatic Patient","volume":"33","author":"Kang","year":"2021","journal-title":"Ann. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e225519","DOI":"10.1136\/bcr-2018-225519","article-title":"Case Report: Death by Antibody","volume":"12","author":"Faccini","year":"2019","journal-title":"BMJ Case Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/adj.12833","article-title":"Concurrent Chronic Hyperplastic Candidosis and Oral Lichenoid Lesion as Adverse Events of Secukinumab Therapy","volume":"66","author":"Farah","year":"2021","journal-title":"Aust. Dent. J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jdcr.2018.04.015","article-title":"Oral Lichenoid Reaction in a Psoriatic Patient Treated with Secukinumab: A Drug-Related Rather than a Class-Related Adverse Event?","volume":"4","author":"Capusan","year":"2018","journal-title":"JAAD Case Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1111\/1346-8138.13637","article-title":"Oral Lichen Planus Associated with Candidiasis during Secukinumab Treatment","volume":"44","author":"Komori","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept Therapy in Rheumatoid Arthritis. A Randomized, Controlled Trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e12817","DOI":"10.1111\/dth.12817","article-title":"Injection Site Reactions with the Use of Biological Agents","volume":"32","author":"Thomaidou","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/bcp.14155","article-title":"Comparison of Pharmacokinetics, Safety and Tolerability of Secukinumab Administered Subcutaneously Using Different Delivery Systems in Healthy Volunteers and in Psoriasis Patients","volume":"86","author":"Bruin","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s13555-019-00341-2","article-title":"Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis","volume":"10","author":"Grace","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40744-020-00245-0","article-title":"Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review","volume":"7","author":"Prignano","year":"2020","journal-title":"Rheumatol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.virol.2014.04.008","article-title":"IL-17 Contributes to Neutrophil Recruitment but Not to Control of Viral Replication During Acute Mouse Adenovirus Type 1 Respiratory Infection","volume":"259","author":"McCarthy","year":"2014","journal-title":"Virology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev-pathol-011110-130318","article-title":"The Th17 Pathway and Inflammatory Diseases of the Intestines, Lungs, and Skin","volume":"8","author":"Weaver","year":"2013","journal-title":"Annu. Rev. Pathol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.idc.2007.08.008","article-title":"Fever of Unknown Origin in Febrile Leukopenia","volume":"21","author":"Antoniadou","year":"2007","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"169","DOI":"10.5152\/eurjrheum.2020.20109","article-title":"The Effect of Secukinumab Treatment on Hematological Parameters in Ankylosing Spondylitis and Psoriatic Arthritis","volume":"7","author":"Koca","year":"2020","journal-title":"Eur. J. Rheumatol."},{"key":"ref_88","first-page":"6287","article-title":"IL-17 and TNF\u03b1 Sustain Neutrophil Recruitment During Inflammation Through Synergistic Effects on Endothelial Activation","volume":"188","author":"Griffin","year":"2012","journal-title":"J. Immunol. Baltim. Md"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fimmu.2022.821598","article-title":"Cancer and Autoimmune Diseases: A Tale of Two Immunological Opposites?","volume":"13","author":"Elkoshi","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamadermatol.2019.3056","article-title":"Association of Psoriasis With the Risk of Developing or Dying of Cancer: A Systematic Review and Meta-Analysis","volume":"155","author":"Trafford","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/annrheumdis-2013-204993","article-title":"Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Women with Systemic Inflammatory Diseases: A Population-Based Cohort Study","volume":"74","author":"Kim","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jamadermatol.2020.0024","article-title":"Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-Analysis","volume":"156","author":"Vaengebjerg","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jaad.2021.07.050","article-title":"Risk of Lymphohematologic Malignancies in Patients with Chronic Plaque Psoriasis: A Systematic Review with Meta-Analysis","volume":"86","author":"Bellinato","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.3892\/ol.2017.6368","article-title":"Ankylosing Spondylitis and the Risk of Cancer","volume":"14","author":"Chang","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bjd.20136","article-title":"The Risk of Malignancy in Patients with Secukinumab-Treated Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Analysis of Clinical Trial and Postmarketing Surveillance Data with up to Five Years of Follow-Up","volume":"185","author":"Lebwohl","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamadermatol.2018.3631","article-title":"Association of Psoriasis With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","volume":"154","author":"Fu","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/abd1806-4841.20153038","article-title":"Psoriasis: Classical and Emerging Comorbidities","volume":"90","author":"Oliveira","year":"2015","journal-title":"An. Bras. Dermatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a Human Anti-IL-17A Monoclonal Antibody, for Moderate to Severe Crohn\u2019s Disease: Unexpected Results of a Randomised, Double-Blind Placebo-Controlled Trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"The Lenercept Multiple Sclerosis Study Group, and The University of British Columbia MS\/MRI Analysis Group (1999). TNF Neutralization in MS. Neurology, 53, 457.","DOI":"10.1212\/WNL.53.3.457"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn\u2019s Disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1093\/rheumatology\/keab193","article-title":"Secukinumab as a Potential Trigger of Inflammatory Bowel Disease in Ankylosing Spondylitis or Psoriatic Arthritis Patients","volume":"60","author":"Onac","year":"2021","journal-title":"Rheumatol. Oxf. Engl."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/cpt.2155","article-title":"IL-17 Inhibitors and Inflammatory Bowel Diseases: A Postmarketing Study in Vigibase","volume":"110","author":"Petitpain","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jaad.2018.06.024","article-title":"Inflammatory Bowel Disease Events after Exposure to Interleukin 17 Inhibitors Secukinumab and Ixekizumab: Postmarketing Analysis from the RADAR (\u201cResearch on Adverse Drug Events And Reports\u201d) Program","volume":"79","author":"Orrell","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_104","first-page":"e16147","article-title":"New-Onset Collagenous Colitis in a Patient With Psoriatic Arthritis: Can It Be Secukinumab?","volume":"13","author":"Obeidat","year":"2021","journal-title":"Cureus"},{"key":"ref_105","first-page":"2975631","article-title":"A Rare Case of New-Onset Ulcerative Colitis Following Initiation of Secukinumab","volume":"2019","author":"Achufusi","year":"2019","journal-title":"Case Rep. Med."},{"key":"ref_106","first-page":"1131","article-title":"Emergence of Inflammatory Bowel Disease During Treatment With Secukinumab","volume":"12","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"9404505","DOI":"10.1155\/2020\/9404505","article-title":"Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the P19 Subunit of IL-23","volume":"2020","author":"Darch","year":"2020","journal-title":"Case Rep. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/ced.14149","article-title":"Severe Colitis Complicating Secukinumab (Cosentyx\u00ae) Therapy","volume":"45","author":"Lee","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_109","first-page":"9679287","article-title":"A Challenging Case of Severe Ulcerative Colitis Following the Initiation of Secukinumab for Ankylosing Spondylitis","volume":"2018","author":"Ehrlich","year":"2018","journal-title":"Case Rep. Gastrointest. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"544","DOI":"10.12968\/hmed.2019.80.9.544","article-title":"A Case of New Onset Ulcerative Colitis Following Secukinumab Treatment","volume":"80","author":"Johnston","year":"2019","journal-title":"Br. J. Hosp. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"E38","DOI":"10.1097\/MIB.0000000000001142","article-title":"Interleukin-17A Inhibitor\u2013Induced Crohn\u2019s Disease\/Beh\u00e7et\u2019s Disease-like Lesions","volume":"23","author":"Shiga","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1684\/ejd.2018.3391","article-title":"Paradoxical Ulcerative Colitis during Treatment with Secukinumab for Psoriasis","volume":"29","author":"Uchida","year":"2019","journal-title":"Eur. J. Dermatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2050313X1989358","DOI":"10.1177\/2050313X19893580","article-title":"Asymptomatic Crohn\u2019s Disease Identified in a Patient Being treatedwith Secukinumab: A Case Report","volume":"7","author":"Haidari","year":"2019","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","article-title":"Risk of Myocardial Infarction in Patients With Psoriasis","volume":"296","author":"Gelfand","year":"2006","journal-title":"JAMA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1038\/jid.2013.149","article-title":"Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis","volume":"133","author":"Samarasekera","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_116","first-page":"51","article-title":"Risk of Coronary Artery Disease in Patients with Ankylosing Spondylitis: A Systematic Review and Meta-Analysis","volume":"3","author":"Ungprasert","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1155\/2012\/714321","article-title":"Cardiovascular Risk in Patients with Psoriatic Arthritis","volume":"2012","author":"Zhu","year":"2012","journal-title":"Int. J. Rheumatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-\u03b1, in Patients with Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy against Congestive Heart Failure (ATTACH) Trial","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1388-9842(02)00121-6","article-title":"Clinical Trials Update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH","volume":"4","author":"Coletta","year":"2002","journal-title":"Eur. J. Heart Fail."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jid.2020.01.025","article-title":"A Randomized Placebo Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate to Severe Plaque Psoriasis (VIP-S)","volume":"140","author":"Gelfand","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_121","first-page":"2071","article-title":"IgA Vasculitis during Secukinumab Therapy","volume":"40","author":"Perkovic","year":"2020","journal-title":"Clin. Rheumatol. 2020 405"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"adv00077-2","DOI":"10.2340\/00015555-3435","article-title":"Cutaneous Vasculitis with Gut Involvement during Secukinumab Treatment for Psoriatic Arthritis","volume":"100","author":"Chelli","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/acr2.11139","article-title":"Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies","volume":"2","author":"Deodhar","year":"2020","journal-title":"ACR Open Rheumatol."},{"key":"ref_124","first-page":"331","article-title":"New-Onset Uveitis Possibly Caused by Secukinumab in a 47-Year-Old Male Patient with Long-Standing Ankylosing Spondylitis","volume":"13","author":"Nadwi","year":"2020","journal-title":"Int. Med. Case Rep. J."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.dsi.2016.10.002","article-title":"Paradoxical Flare of Psoriasis, Psoriatic Spondyloarthritis, and Psoriatic Uveitis after Switching from Infliximab to Secukinumab","volume":"35","author":"Su","year":"2017","journal-title":"Dermatol. Sin."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1750-1172-7-57","article-title":"Uveitis\u2014A Rare Disease Often Associated with Systemic Diseases and Infections\u2014A Systematic Review of 2619 Patients","volume":"7","author":"MacA","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"594735","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL-23\/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside","volume":"11","author":"Liu","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2050313X2090456","DOI":"10.1177\/2050313X20904561","article-title":"Dyshidrotic Eczema in Two Patients on Secukinumab for Plaque: A Case Report","volume":"8","author":"Bose","year":"2020","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_129","first-page":"e13150","article-title":"Secukinumab-Induced Paradoxical Hidradenitis Suppurativa","volume":"33","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1001\/jamadermatol.2017.2826","article-title":"Secukinumab-Induced Psoriasiform Eruption","volume":"153","author":"Sladden","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1590\/abd1806-4841.20176481","article-title":"Biologic Therapy-Induced Pemphigus","volume":"92","author":"Hayashida","year":"2017","journal-title":"An. Bras. Dermatol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1128\/CVI.00061-11","article-title":"Distinct Effects of Anti-Tumor Necrosis Factor Combined Therapy on TH1\/TH2 Balance in Rheumatoid Arthritis Patients","volume":"18","author":"Herman","year":"2011","journal-title":"Clin. Vaccine Immunol. CVI"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jaad.2017.08.024","article-title":"Psychiatric Adverse Events during Treatment with Brodalumab: Analysis of Psoriasis Clinical Trials","volume":"78","author":"Lebwohl","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s13555-020-00472-x","article-title":"Two-Year US Pharmacovigilance Report on Brodalumab","volume":"11","author":"Lebwohl","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3389\/fimmu.2019.01696","article-title":"The Role of Inflammation in Depression and Fatigue","volume":"10","author":"Lee","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbi.2010.10.010","article-title":"Cytokine Levels in the Blood May Distinguish Suicide Attempters from Depressed Patients","volume":"25","author":"Janelidze","year":"2011","journal-title":"Brain. Behav. Immun."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1756-185X.2011.01673.x","article-title":"The Role of Interleukin (IL)-17 in Anxiety and Depression of Patients with Rheumatoid Arthritis","volume":"15","author":"Liu","year":"2012","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1111\/bjd.16051","article-title":"No Elevated Risk for Depression, Anxiety or Suicidality with Secukinumab in a Pooled Analysis of Data from 10 Clinical Studies in Moderate-to-Severe Plaque Psoriasis","volume":"178","author":"Strober","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1684\/ejd.2016.2832","article-title":"Exacerbation of Depression in a Psoriatic Arthritis Patient Possibly Induced by Secukinumab","volume":"26","author":"Komori","year":"2016","journal-title":"Eur. J. Dermatol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5070\/D3256044449","article-title":"Bullous Acral Eruption Related to Secukinumab","volume":"25","author":"Blackcloud","year":"2019","journal-title":"Dermatol. Online J."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5070\/D3264048363","article-title":"Secukinumab-Induced Pompholyx in a Psoriasis Patient","volume":"26","author":"Eichhoff","year":"2020","journal-title":"Dermatol. Online J."},{"key":"ref_142","first-page":"1","article-title":"Granuloma Annulare in the Setting of Secukinumab","volume":"2018","author":"Clark","year":"2018","journal-title":"Case Rep. Dermatol. Med."},{"key":"ref_143","first-page":"1","article-title":"A Case of Granuloma Annulare Associated with Secukinumab Use","volume":"2017","author":"Bonomo","year":"2017","journal-title":"Case Rep. Dermatol. Med."},{"key":"ref_144","first-page":"6760806","article-title":"Relapsing Polychondritis Following Treatment with Secukinumab for Ankylosing Spondylitis: Case Report and Review of the Literature","volume":"2018","author":"Zheutlin","year":"2018","journal-title":"Case Rep. Rheumatol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/1574886314666190726155147","article-title":"A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report","volume":"15","author":"Dastoli","year":"2020","journal-title":"Curr. Drug Saf."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.1111\/jdv.14248","article-title":"Adverse Skin Reaction to Secukinumab","volume":"31","author":"Peigottu","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1111\/ajd.12664","article-title":"Recurrent Angular Cheilitis after Secukinumab Injections","volume":"59","author":"Hitaka","year":"2018","journal-title":"Australas. J. Dermatol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1684\/ejd.2016.2900","article-title":"Drug Eruption Caused by Secukinumab","volume":"27","author":"Shibata","year":"2017","journal-title":"Eur. J. Dermatol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jdcr.2016.07.009","article-title":"Severe, Ulcerative, Lichenoid Mucositis Associated with Secukinumab","volume":"2","author":"Thompson","year":"2016","journal-title":"JAAD Case Rep."},{"key":"ref_150","first-page":"003099","article-title":"Secukinumab, Pituitary Enlargement and Panhypopituitarism: Are They Related?","volume":"8","author":"Ramalho","year":"2021","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"E494","DOI":"10.1111\/1346-8138.16041","article-title":"Cutaneous Sarcoidosis after Application of Secukinumab in a Patient with Plaque Psoriasis","volume":"48","author":"Lu","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/03009742.2019.1594359","article-title":"New Onset of Psoriasis Induced by Secukinumab in a Patient with Ankylosing Spondylitis: A Case Report","volume":"49","author":"Currado","year":"2019","journal-title":"Scand. J. Rheumatol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4103\/ijdvl.IJDVL_872_19","article-title":"Superficial Thrombophlebitis during Secukinumab Treatment in a Patient with Psoriasis","volume":"86","author":"Mammadli","year":"2020","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jdcr.2021.03.052","article-title":"Palmoplantar Pompholyx Secondary to Interleukin 17A Inhibitor Therapy for Psoriasis: A Case Series","volume":"13","author":"Peera","year":"2021","journal-title":"JAAD Case Rep."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00105-017-4071-8","article-title":"Secukinumab-Induzierter Subakut-Kutaner Lupus Erythematodes","volume":"69","author":"Wehrmann","year":"2017","journal-title":"Hautarzt"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000513467","article-title":"Atopic Dermatitis as a Paradoxical Effect of Secukinumab for the Treatment of Psoriasis","volume":"13","author":"Brambilla","year":"2021","journal-title":"Case Rep. Dermatol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/omcr\/omz041","article-title":"Secukinumab Induced Beh\u00e7et\u2019s Syndrome: A Report of Two Cases","volume":"2019","author":"Dincses","year":"2019","journal-title":"Oxf. Med. Case Rep."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"e15048","DOI":"10.1111\/dth.15048","article-title":"Secukinumab-Induced Multiple Lentigines in Areas of Resolved Psoriatic Plaques: A Case Report and Literature Review","volume":"34","author":"Zhang","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4103\/0378-6323.115526","article-title":"Tumor Necrosis Factor-\u03b1 Antagonists: Side Effects and Their Management","volume":"79","author":"Dogra","year":"2013","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2042098620905976","DOI":"10.1177\/2042098620905976","article-title":"Secukinumab-Induced Raynaud\u2019s Phenomenon: First Report in the Literature","volume":"11","author":"Kobak","year":"2020","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.amjmed.2021.01.018","article-title":"Aphthous Stomatitis in a Man with Psoriatic Arthritis","volume":"134","author":"Fermon","year":"2021","journal-title":"Am. J. Med."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000510831","article-title":"Vitiligo with Progressive Repigmentation during Secukinumab Treatment in a Patient with Psoriatic Arthritis: A Case Report","volume":"13","author":"Giordano","year":"2021","journal-title":"Case Rep. Dermatol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/ICO.0000000000001789","article-title":"Secukinumab-Associated Crystalline Corneal Deposition","volume":"38","author":"Power","year":"2019","journal-title":"Cornea"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"240615","DOI":"10.1136\/bcr-2020-240615","article-title":"Sarcoidosis Manifesting during Treatment with Secukinumab for Psoriatic Arthritis","volume":"14","author":"Kirby","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1093\/rheumatology\/keaa603","article-title":"Secukinumab-Induced Scleroderma: A Case Report","volume":"60","author":"Elias","year":"2021","journal-title":"Rheumatology"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jdcr.2020.06.011","article-title":"Pyoderma Gangrenosum Induced by Secukinumab in a Patient with Psoriasis Successfully Treated with Ustekinumab","volume":"6","author":"Petty","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1111\/jdv.14622","article-title":"Three Cases of Facial Erythema with Dryness and Pruritus in Psoriasis Patients during Treatment with IL-17 Inhibitors","volume":"32","author":"Oiwa","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjd.17424","article-title":"Paradoxical Exacerbation of Latent Interstitial Pneumonia by Secukinumab in a Patient with Psoriasis Vulgaris","volume":"180","author":"Hayashi","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1111\/1346-8138.13986","article-title":"Secukinumab-Induced Interstitial Pneumonia in a Patient with Psoriasis Vulgaris","volume":"44","author":"Kajihara","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e12505","DOI":"10.1111\/dth.12505","article-title":"Anti IL-17 Flared Psoriasis in a Patient on Secukinumab","volume":"30","author":"Noell","year":"2017","journal-title":"Dermatol. Ther."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jamadermatol.2015.4992","article-title":"Perianal Dermatophytosis During Secukinumab Therapy for Plaque Psoriasis","volume":"152","author":"Quach","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1111\/1346-8138.13909","article-title":"Development of Bullous Pemphigoid during Secukinumab Treatment for Psoriasis","volume":"44","author":"Ho","year":"2017","journal-title":"J. Dermatol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1111\/ajd.13009","article-title":"Pseudolymphoma Induced by Secukinumab for Treatment of Chronic Plaque Psoriasis","volume":"60","author":"Cranwell","year":"2019","journal-title":"Australas. J. Dermatol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1111\/1346-8138.14611","article-title":"Pyoderma Gangrenosum Triggered by Switching from Adalimumab to Secukinumab","volume":"46","author":"Jin","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jdcr.2020.08.028","article-title":"Herpetiform Aphthous Ulcerations Induced by Secukinumab: Report of 2 Cases","volume":"6","author":"Benzaquen","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e12751","DOI":"10.1111\/dth.12751","article-title":"Atopic-like Dermatitis after Secukinumab Injection: A Case Report","volume":"32","author":"Burlando","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/ced.13375","article-title":"Paradoxical Localized Exacerbation of Psoriatic Eruptions Triggered by Secukinumab","volume":"43","author":"Hoshina","year":"2018","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_178","first-page":"e13161","article-title":"Pyoderma Gangrenosum Induced by Secukinumab\u2014A Late Paradoxical Drug Reaction","volume":"33","author":"Wollina","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_179","first-page":"5213876","article-title":"Novel Presentation of Terminal Ileitis Associated with Secukinumab Therapy","volume":"2021","author":"Shaheen","year":"2021","journal-title":"Case Rep. Gastrointest. Med."},{"key":"ref_180","first-page":"41","article-title":"Possible Autoimmune Hemolytic Anemia Induced by Secukinumab: A Case Report","volume":"41","author":"Rahman","year":"2022","journal-title":"Pan Afr. Med. J."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/bjd.16901","article-title":"Secukinumab in Pregnancy: Outcomes in Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis from the Global Safety Database","volume":"179","author":"Warren","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40272-021-00476-w","article-title":"Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis","volume":"23","author":"Blair","year":"2021","journal-title":"Paediatr. Drugs"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/ced.14258","article-title":"Real-Life Efficacy and Safety of Secukinumab in Elderly Patients with Psoriasis over a 2-Year Period","volume":"45","author":"Megna","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/19420862.2016.1171431","article-title":"Evaluating Imbalances of Adverse Events during Biosimilar Development","volume":"8","author":"Vana","year":"2016","journal-title":"mAbs"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/11\/1365\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:12:04Z","timestamp":1760145124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/11\/1365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":184,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["ph15111365"],"URL":"https:\/\/doi.org\/10.3390\/ph15111365","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]}}}